Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
McKesson
Dow
Colorcon
Moodys

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Fluoxetine hydrochloride; olanzapine - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for fluoxetine hydrochloride; olanzapine and what is the scope of freedom to operate?

Fluoxetine hydrochloride; olanzapine is the generic ingredient in two branded drugs marketed by Par Pharm, Sandoz, Teva Pharms, and Lilly, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-seven drug master file entries for fluoxetine hydrochloride; olanzapine. Five suppliers are listed for this compound.

Recent Clinical Trials for fluoxetine hydrochloride; olanzapine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Massachusetts General HospitalEarly Phase 1
CGStat LLCN/A
Patient-Centered Outcomes Research InstituteN/A

See all fluoxetine hydrochloride; olanzapine clinical trials

Recent Litigation for fluoxetine hydrochloride; olanzapine

Identify potential future generic entrants

District Court Litigation
Case NameDate
ALCON MANUFACTURING, LTD v. APOTEX INC.2006-11-15
Dow Chemical Company v. Nova Chemicals Corporation2005-10-21
Bayer AG v. Dr. Reddy's Lab.Ltd.2004-03-24

See all fluoxetine hydrochloride; olanzapine litigation

Pharmacology for fluoxetine hydrochloride; olanzapine
Paragraph IV (Patent) Challenges for FLUOXETINE HYDROCHLORIDE; OLANZAPINE
Tradename Dosage Ingredient NDA Submissiondate
SYMBYAX CAPSULE;ORAL fluoxetine hydrochloride; olanzapine 021520 2005-01-10

US Patents and Regulatory Information for fluoxetine hydrochloride; olanzapine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms OLANZAPINE AND FLUOXETINE HYDROCHLORIDE fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 077528-001 Jun 19, 2012 AB RX No No   Start Trial   Start Trial   Start Trial
Lilly SYMBYAX fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 021520-002 Dec 24, 2003 AB RX Yes No   Start Trial   Start Trial   Start Trial
Lilly SYMBYAX fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 021520-004 Dec 24, 2003 AB RX Yes No   Start Trial   Start Trial   Start Trial
Teva Pharms OLANZAPINE AND FLUOXETINE HYDROCHLORIDE fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 077528-002 Jun 19, 2012 AB RX No No   Start Trial   Start Trial   Start Trial
Lilly SYMBYAX fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 021520-005 Dec 24, 2003 AB RX Yes No   Start Trial   Start Trial   Start Trial
Par Pharm OLANZAPINE AND FLUOXETINE HYDROCHLORIDE fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 077742-003 Nov 2, 2012 AB RX No No   Start Trial   Start Trial   Start Trial
Par Pharm OLANZAPINE AND FLUOXETINE HYDROCHLORIDE fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 077742-004 Nov 2, 2012 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for fluoxetine hydrochloride; olanzapine

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Moodys
AstraZeneca
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.